by Thomas et al. 5 and observed by Crossman et al. 6 in patients with chronic myeloid leukemia.
Identification and characterization of new somatic mutations in cancer-related genes during leukemogenesis are allowing to perform more accurate molecular classification of the diseases and subsequently, to select better risk-adapted therapies. Although the number and type of these gene alterations are continuously increasing, we still need a detailed picture of relevant changes that can give significant prognostic information. In acute myeloid leukaemia (AML), cytogenetically normal patients cluster a heterogeneous group with an intermediate-risk prognostic category. In recent years, several genetic alterations have been shown to affect clinical outcomes in this group of AML patients with normal karyotype (NK). 1 Of relevant importance are FLT3 ITD and NPM1 mutations, which are present in around 30% and up to 60% respectively of AML-NK patients. Large leukaemia study groups have showed up association between NPM1 and FLT3 mutations regarding clinical outcome. Thus, most of the studies found that NPM1 mutations, in the absence of FLT3-ITD, are associated with a significantly improved outcome (most studies cited and reviewed by Mró zek et al. 1 and Falini et al. 2 ). The good prognostic mutations in NPM1 comprise changes in exon 12 of the gene, mainly consisting of a 4 bp duplication that causes a shift in the reading frame leading to a replacement of the last seven amino acids by 11 different ones in the C-terminal part of the protein. These alterations modify one or two critical Trp residues in the terminal part of the molecule and create a new nuclear export signal motif, causing delocalization of NPM1 protein from its normal nucleolar localization to the cytoplasm. This feature of the mutant proteins has also allowed detecting them by immunohistochemical methods, since 'normal' proteins are mainly located at the nucleolus while the 'mutated' are cytoplasmic. Since the first description of exon 12 mutations in NPM1 gene, more than 30 different 4 bp insertion or insertion/ deletion have been described, leading all of them to a fouramino-acid longer protein with a new nuclear export signal motif. 2 We report the detection of a new mutation caused by an eight nucleotide-insertion in NPM1 gene in a patient with AML-NK who suffered an early relapse of her disease. This alteration leads to a truncated protein lacking 20 amino acids at the C-terminal end. We discuss here the potential relevance of this alteration in the context of the still heterogeneous intermediate group of AML-NK.
To provide prognostic significance of NPM1 and FLT3 mutations in normal karyotype de novo diagnosed AML patients at our institution, we studied the presence of alterations in those genes in samples of bone marrow obtained at diagnosis. RNA was purified from bone marrow and cDNA was synthesized by standard methods. A set of oligonucleotides was designed to amplify a segment of NPM1 cDNA comprising exons 11 and 12 of the molecule (5 0 -6FAM-GGTGGTTCTCTTCCCAAAGT and 5 0 -AACATTTATCAAACACGGTA), and a segment of FLT3 comprising exons 13 and 14 (5 0 -AAACTCTCCAGGCCCCTTCC and 5
0 -HEX-CTGATCCTAGTACCTTCCCAAA). One of each pair of oligonucleotides was fluorescent labelled to analyse the amplified products by capillary electrophoresis in a single run by an ABIPrism 310 Genetic Analyzer. Within the group of 38 AML patients analysed, we found nine alterations in the NPM1-amplified fragment, most of them being a fragment fournucleotide longer than the wild type. Sequencing analysis of the fragments with altered pattern revealed that most of the mutations were type A (960_963dupTCTG) (six cases), followed by one case of each type B (960_963insCATG), type D (960_963insCCTG) and type 4 (960_963insCTTG). 2 However, we found a different migration pattern in an amplified NPM1 fragment from an AML patient cDNA. This fragment was eight nucleotides longer than the normal type ( Figure 1a ). Sequencing analysis revealed that this patient was heterozygous for a novel mutation consisting of an 8 bp insertion in a region of the NPM1 exon 11 (Figure 1b) . This insertion causes a frameshift with six new amino acids added after amino acid number 268 and then a stop codon at the level of the amino acid number 274 with a subsequent deletion of the last 20 amino acids (GenBank accession number EF429251). The patient harbouring this novel mutation was a 70-year-old female. At diagnosis, she had 53% blast cells counted in bone marrow aspirate, normal karyotype, unmutated FLT3 and no other genetic alterations detected (no 11q23 translocations or t(8;21), inv(16) or t(15;17)). The patient was treated with idarubicin and cytosine arabinoside (ara-C) as induction therapy followed by two cycles of high doses ara-C as consolidation. Relapse occurred 9 months after diagnosis. Analysis of NPM1 mutations in RNA from bone marrow at relapse revealed the presence of the same genetic alteration detected at diagnosis.
We studied the cellular location of the NPM1 truncated protein by immunofluorescence using mononuclear cells isolated from this patient's bone marrow at relapse. Confocal laser microscopy in mononuclear cells, heterozygous for the novel truncating mutation, showed a nucleolar staining of NPM1 in addition to some diffuse staining in the nucleus and cytoplasm (Figure 2c ). This pattern of staining is intermediate between that observed in HeLa cells (Figure 2a) , where a clear nucleolar staining pattern is detected, and the observed pattern in 'type A' NPM1 mutation, with an intense scattered distribution pattern between nucleus and cytoplasm ( Figure 2b) .
Biological role of this truncated protein is not known at present. According to the functional domains described for NPM1 protein, it is interesting to point out that although the truncated mutant protein lacks the two Trp residues that have been implicated in nucleolar location, the pattern of staining observed in the heterozygous sample still retains some of this localization. It is tempting to speculate that in this case the wildtype protein would not be 'sequestered' in the cytoplasm when forming heterodimers with the mutant protein, as has been suggested to occur with the described exon 12-NPM1 mutants. 2 It is also remarkable that the lack of 20 C-terminal residues in the mutant protein resembles one of the two known NPM1 isoforms that have been associated with cellular resistance to ionizing radiation. 3 We want to bring attention to some significant unsolved issues. Frequency of this new mutation in AML population is unknown at present, since all large studies where NPM1 mutations were determined only involved exon 12 amplification from genomic DNA or use of specific probes for known mutations precluding exon 11 region [4] [5] [6] [7] (see references cited in Mrozek et al .1 ), which let in all cases this new truncation mutation go unnoticed. Even recommended immunohistochemical determinations 2 may have failed detecting this alteration, due to its mixed staining pattern. New analyses of the thousands of samples available in large leukaemia study groups would allow to obtain the frequency for this new type of NPM1 mutation, thus opening the possibility of redefining new subclasses of AML-NK based in these molecular findings. At this point, it is interesting to add that in their recent review 2 Falini et al. mentioned an abstract where the presence of an exon 11 mutation in an AML patient is described (Albiero et al. Haematologica 2006; 91: 237, abstract). The reported mutation at exon 11 is the same kind of eight nucleotide insertion as the one we have found and reported here, but the inserted nucleotides are different in sequence, although both alterations produce a similar truncated protein. These data reinforce the possibility that a new hot spot for insertional mutation in NPM1 might have been located and strengthen the need for establishing the frequency of this type of mutation in AML patients as well as the biological consequences of this new finding. 1 
